AML Comprehensive Panel

The AML Comprehensive Panel is critical for the diagnosis and risk stratification of AML. It provides detailed information on cellular characteristics, chromosomal abnormalities, and specific gene mutations, helping doctors formulate a personalized treatment plan for patients.

No, there is no need to fast before undergoing the AML Comprehensive Panel.

This panel provides a wealth of information including cellular characteristics through flow cytometry, chromosomal number and structure through karyotyping, specific DNA sequences through FISH, and mutations in the FLT3, NPM1, and CEBPA genes.

The frequency of the test depends on the doctor’s recommendations and the patient's condition. It's typically performed at diagnosis and may be repeated to monitor response to treatment or check for recurrence.

The risks are minimal and are mainly related to the collection of the blood or bone marrow sample. These may include discomfort, bruising, and, in rare cases, infection.

Normal values indicate the absence of the AML-related abnormalities. However, results can vary, and it is essential to have them interpreted by your doctor.

No specific precautions are required, but it is essential to inform your doctor about any medications or supplements you are taking.

If the test values are abnormal, it is advisable to consult a hematologist or oncologist.

Yes, by identifying specific genetic mutations and chromosomal abnormalities, the AML Comprehensive Panel can help in predicting the course of the disease and the likely response to therapy.

By providing detailed information on the genetic makeup of the leukemia cells, this panel helps doctors to choose the most effective treatment strategies, which can include chemotherapy, targeted therapy, or stem cell transplant.

FLT3 is a gene often mutated in AML, and it plays a role in the growth of cancer cells. Identifying FLT3 mutations helps in predicting prognosis and can guide treatment decisions.

NPM1 and CEBPA are genes that can be mutated in AML. Like FLT3, mutations in these genes are essential for prognosis and can be targets for specific therapies.

Chromosomal abnormalities in AML are often associated with how aggressive the disease is and how it responds to treatment. Identifying these abnormalities helps in risk stratification and treatment planning.

Yes, the AML Comprehensive Panel can be used to monitor the effectiveness of treatment by tracking changes in cellular characteristics and genetic markers over time.

The AML Comprehensive Panel is an essential tool for diagnosing and managing Acute Myeloid Leukemia. This panel combines several diagnostic tests to provide a comprehensive overview of the genetic and cellular characteristics of the disease. It is crucial for patients diagnosed with AML to discuss the results of this panel with their doctor to understand the implications for treatment and prognosis. This information is essential in developing a personalized treatment plan tailored to the specific characteristics of the patient’s disease. Regular monitoring through the AML Comprehensive Panel can also be vital in assessing the effectiveness of treatment and making necessary adjustments.